A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.52 USD -1.95% Market Closed
Market Cap: 321m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Aquestive Therapeutics Inc
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Tax Provision
-$101k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Tax Provision
-$2.9B
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Tax Provision
-$367m
CAGR 3-Years
32%
CAGR 5-Years
17%
CAGR 10-Years
4%
Pfizer Inc
NYSE:PFE
Tax Provision
$402m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Tax Provision
-$1.6B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Tax Provision
-$1.8B
CAGR 3-Years
-30%
CAGR 5-Years
-80%
CAGR 10-Years
-10%
No Stocks Found

Aquestive Therapeutics Inc
Glance View

Market Cap
320.9m USD
Industry
Pharmaceuticals

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
2.06 USD
Overvaluation 42%
Intrinsic Value
Price
A

See Also

What is Aquestive Therapeutics Inc's Tax Provision?
Tax Provision
-101k USD

Based on the financial report for Sep 30, 2024, Aquestive Therapeutics Inc's Tax Provision amounts to -101k USD.

What is Aquestive Therapeutics Inc's Tax Provision growth rate?
Tax Provision CAGR 1Y
28%

Over the last year, the Tax Provision growth was 28%.

Back to Top